Ngaio Bealum is one of the premiere cannabis comics in the United States and you’ll see why he has performed at just about every Hempfest on the West Coast and too many cannabis-related events to even keep track of. He has appeared on Comedy Central, BET, MTV and many other networks and shows across your television dial. Very recently, he was a featured guest on the hilarious podcast of Doug Benson (Super High Me, Half-Baked), Getting Doug With High. In addition to his cannabis comedy, he is the former editor of West Coast Cannabis Magazine and has been a tireless activist for legalization. While Ngaio’s comedy is hilarious whether you are a full-fledged member of the cannabis community or not, it certainly doesn’t hurt.

Peter Homberg specialises in life sciences, IP and corporate law, and M&A transactions.

He particularly advises companies in the pharmaceutical, diagnostics, medical device and biotechnology sectors on research and development contracts, collaboration agreements, cross-border IP licensing and IP strategies. He also has extensive experience in advising on compliance issues and advises companies extensively in the field of medical cannabis.

Peter is a frequent speaker at seminars and conferences and is the author of numerous articles and other publications on corporate or IP law in the areas of life sciences and medical cannabis. In addition, he has extensive transaction experience in Southeast Asia.

His clients include:

• Start-ups
• Medium-sized companies
• Listed companies
• Nationally and internationally operating corporate groups
• Financial investors
• Strategic investors

Experience Highlights
DEMECAN GmbH: Preparation of a legal opinion on the compatibility of the legalization of cannabis for recreational purposes in Germany with international and European law. Identification of possible solutions to overcome obstacles under international and European law.

Canopy Growth Corp.: Advising the subsidiary of one of Canada’s leading medical cannabis providers in connection with the acquisition of the Storz & Bickel GmbH & Co. KG group of companies for a total of €135 million.

DEMECAN GmbH: Preparation of a comprehensive legal opinion on the legal hurdles to the legalization of cannabis for recreational purposes and analysis of possible legal solutions.
Proteona Pte. Ltd.: Advising the biotechnology company on the conclusion of an exclusive worldwide license agreement with the National University of Singapore (NUS).
Canadian supplier of medical cannabis: Advising in connection with the conclusion of a joint venture agreement with a German wholesaler of pharmaceuticals.

Scil Technology GmbH: Advising on the out-licensing of a program for the regenerative treatment of osteoarthritis and cartilage defects to Sanofi.
Scil Technology GmbH: Advising on the sale of its service and production division to Nanohale AG.
German biotechnology company: Advising on the sale of a technology for the treatment of certain forms of heart failure.

German mid-sized pharmaceutical company: Advising on the out-licensing and distribution of an API for the treatment of interstitial cystitis to a US-based multinational pharmaceutical company.
Large US-based pharmaceutical company: Advising on the due diligence of a technology portfolio in advance of the in-licensing of a technology for the production of vaccines.

Swiss biotech company: Advising on a planned collaboration with a French multinational pharmaceutical company.

German-Singaporean biotech company: Advising on the in-licensing of a key diagnostic technology from the National University of Singapore.

French venture capital fund: Advising on the acquisition of a block of shares in a German biotech company.

Medium-sized pharmaceutical company: Advising on the restructuring of sales in Portugal and various other European countries.

Various clients: Advising in connection with transactions in the life sciences sector, including technology transfer agreements, research and development agreements, corporate transactions (mergers & acquisitions), private equity transactions, arbitration proceedings and litigation.

Peter Homberg specialises in life sciences, IP and corporate law, and M&A transactions.

He particularly advises companies in the pharmaceutical, diagnostics, medical device and biotechnology sectors on research and development contracts, collaboration agreements, cross-border IP licensing and IP strategies. He also has extensive experience in advising on compliance issues and advises companies extensively in the field of medical cannabis.

Peter is a frequent speaker at seminars and conferences and is the author of numerous articles and other publications on corporate or IP law in the areas of life sciences and medical cannabis. In addition, he has extensive transaction experience in Southeast Asia.

His clients include:

• Start-ups
• Medium-sized companies
• Listed companies
• Nationally and internationally operating corporate groups
• Financial investors
• Strategic investors

Experience Highlights
DEMECAN GmbH: Preparation of a legal opinion on the compatibility of the legalization of cannabis for recreational purposes in Germany with international and European law. Identification of possible solutions to overcome obstacles under international and European law.

Canopy Growth Corp.: Advising the subsidiary of one of Canada’s leading medical cannabis providers in connection with the acquisition of the Storz & Bickel GmbH & Co. KG group of companies for a total of €135 million.

DEMECAN GmbH: Preparation of a comprehensive legal opinion on the legal hurdles to the legalization of cannabis for recreational purposes and analysis of possible legal solutions.
Proteona Pte. Ltd.: Advising the biotechnology company on the conclusion of an exclusive worldwide license agreement with the National University of Singapore (NUS).
Canadian supplier of medical cannabis: Advising in connection with the conclusion of a joint venture agreement with a German wholesaler of pharmaceuticals.

Scil Technology GmbH: Advising on the out-licensing of a program for the regenerative treatment of osteoarthritis and cartilage defects to Sanofi.
Scil Technology GmbH: Advising on the sale of its service and production division to Nanohale AG.
German biotechnology company: Advising on the sale of a technology for the treatment of certain forms of heart failure.

German mid-sized pharmaceutical company: Advising on the out-licensing and distribution of an API for the treatment of interstitial cystitis to a US-based multinational pharmaceutical company.
Large US-based pharmaceutical company: Advising on the due diligence of a technology portfolio in advance of the in-licensing of a technology for the production of vaccines.

Swiss biotech company: Advising on a planned collaboration with a French multinational pharmaceutical company.

German-Singaporean biotech company: Advising on the in-licensing of a key diagnostic technology from the National University of Singapore.

French venture capital fund: Advising on the acquisition of a block of shares in a German biotech company.

Medium-sized pharmaceutical company: Advising on the restructuring of sales in Portugal and various other European countries.

Various clients: Advising in connection with transactions in the life sciences sector, including technology transfer agreements, research and development agreements, corporate transactions (mergers & acquisitions), private equity transactions, arbitration proceedings and litigation.

Peter Homberg specialises in life sciences, IP and corporate law, and M&A transactions.

He particularly advises companies in the pharmaceutical, diagnostics, medical device and biotechnology sectors on research and development contracts, collaboration agreements, cross-border IP licensing and IP strategies. He also has extensive experience in advising on compliance issues and advises companies extensively in the field of medical cannabis.

Peter is a frequent speaker at seminars and conferences and is the author of numerous articles and other publications on corporate or IP law in the areas of life sciences and medical cannabis. In addition, he has extensive transaction experience in Southeast Asia.

His clients include:

• Start-ups
• Medium-sized companies
• Listed companies
• Nationally and internationally operating corporate groups
• Financial investors
• Strategic investors

Experience Highlights
DEMECAN GmbH: Preparation of a legal opinion on the compatibility of the legalization of cannabis for recreational purposes in Germany with international and European law. Identification of possible solutions to overcome obstacles under international and European law.

Canopy Growth Corp.: Advising the subsidiary of one of Canada’s leading medical cannabis providers in connection with the acquisition of the Storz & Bickel GmbH & Co. KG group of companies for a total of €135 million.

DEMECAN GmbH: Preparation of a comprehensive legal opinion on the legal hurdles to the legalization of cannabis for recreational purposes and analysis of possible legal solutions.
Proteona Pte. Ltd.: Advising the biotechnology company on the conclusion of an exclusive worldwide license agreement with the National University of Singapore (NUS).
Canadian supplier of medical cannabis: Advising in connection with the conclusion of a joint venture agreement with a German wholesaler of pharmaceuticals.

Scil Technology GmbH: Advising on the out-licensing of a program for the regenerative treatment of osteoarthritis and cartilage defects to Sanofi.
Scil Technology GmbH: Advising on the sale of its service and production division to Nanohale AG.
German biotechnology company: Advising on the sale of a technology for the treatment of certain forms of heart failure.

German mid-sized pharmaceutical company: Advising on the out-licensing and distribution of an API for the treatment of interstitial cystitis to a US-based multinational pharmaceutical company.
Large US-based pharmaceutical company: Advising on the due diligence of a technology portfolio in advance of the in-licensing of a technology for the production of vaccines.

Swiss biotech company: Advising on a planned collaboration with a French multinational pharmaceutical company.

German-Singaporean biotech company: Advising on the in-licensing of a key diagnostic technology from the National University of Singapore.

French venture capital fund: Advising on the acquisition of a block of shares in a German biotech company.

Medium-sized pharmaceutical company: Advising on the restructuring of sales in Portugal and various other European countries.

Various clients: Advising in connection with transactions in the life sciences sector, including technology transfer agreements, research and development agreements, corporate transactions (mergers & acquisitions), private equity transactions, arbitration proceedings and litigation.

George Bellow is a visionary entrepreneur and strategic leader with over 16 years of experience in sales, business development, and startup growth across industries like pharmaceuticals, virtual reality, and fintech. As Co-Founder of SOMAÍ Pharmaceuticals, George successfully raised €30 million, playing a pivotal role in establishing the company’s sales and distribution networks across Europe. His work secured partnerships in key markets such as Germany, the UK, Switzerland, and Poland, positioning SOMAÍ as a leading name in the European medical cannabis sector.

Before SOMAÍ, George founded Belka VR, a trailblazing virtual reality company that gained global recognition. He also spearheaded international sales growth for UNICUM, expanding its reach to over 24 countries. In Russia, George co-founded Mili, a fintech pioneer in microloans, scaling it to become the largest provider in the country with over $13 million in revenue before a successful exit. His strategic foresight helped raise €5 million for Mili, fueling its rapid growth and market leadership.

With executive education from MIT Sloan and an MBA from Moscow School of Management Skolkovo, George brings unmatched expertise in strategic planning, capital raising, and business scaling, driving impactful results and innovation in every venture he leads.

Physician and natural scientist Dr. Adrian Fischer founded DEMECAN in 2017, together with his fellow students Dr. Constantin von der Groeben (lawyer) and Dr. Cornelius Maurer (economist). Their goal: to guarantee patients in Germany access to medical cannabis of the highest pharmaceutical quality “Made in Germany”. Today, DEMECAN operates as the only independent German producer of medical cannabis on behalf of the Federal Institute for Drugs and Medical Devices (BfArM) and runs Europe’s largest indoor production facility for medical cannabis in Saxony.

Dr. Adrian Fischer developed the cultivation concept of medicinal cannabis and coordinated the  expansion of the production facility near Dresden. He is responsible for the company’s own cultivation of cannabis, the production of cannabis products according to pharmaceutical standards and the research cultivation on the 100,000 sqm site in Ebersbach near Dresden. His responsibilities also include quality management and communication with physicians, pharmacists and other professional stakeholders.

Fischer completed his medical studies in Cologne and Boston. As part of his dissertation, he conducted pharmacological studies as a study physician and received his doctorate in 2015 for his dissertation, which was awarded the best scientific doctoral thesis of the year. The results of his studies on the mode of action of antidepressants in humans were awarded the prize for the most important research paper of the year by the European Psychiatric Association (EPA) and have been published in the most  prestigious international journals. Dr. Fischer has received numerous other awards, including from the German Psychological Society, and his research has been reported in Time Magazine.

During his research on complex neuromodulatory and transmitter systems involved in pain regulation, he also focused on the mechanism of action of cannabinoids. Dr. Fischer quickly recognized the potential of the active ingredients of the cannabis plant, but also the lack of offers in Germany and the educational work that still needs to be done to free doctors, health insurers and patients from prejudices.

In addition to his research work, he was employed at the hospital. There, the native of Freiburg had to adjust to new extreme situations again and again. This prepared him for the turbulent time as a founder and entrepreneur in a newly emerging market.

With DEMECAN, he wants to continue researching medicinal cannabis, because although cannabis has been used as a medicinal and useful plant for a long time, research is still in its infancy worldwide, especially in Germany.

Dr. Adrian Fischer is an expert and speaker on the following topics:

• Cultivation and further processing of medicinal cannabis
• Pain therapy with cannabis
• The active ingredients of the cannabis plant
• GMP requirements and pharmaceutical standards
• Neurobiology

Jürgen Bickel is the Managing Director and co-founder of STORZ & BICKEL, a manufacturer of high-quality medical vaporizers based in Tuttlingen, Germany. The brand’s most famous device, the VOLCANO, was the first medically certified cannabis vaporizer worldwide and remains the gold standard among physicians, researchers, and consumers.

Jürgen Bickel holds a degree in civil engineering and, prior to starting at STORZ & BICKEL, managed a development aid project for drinking water supply in Peru for 5 years. His experience in planning and organizing large-scale projects was of great benefit to him as Managing Director of STORZ & BICKEL, and together with Markus Storz, he established the successful, globally operating brand.

Today, the company looks back on more than 24 years in the industry, remaining a pioneer and world market leader in the sector thanks to the visionary thinking of the founders.

Find out more about Jürgen Bickel on Linkedin and Instagram.

Jamie Pearson has been a highly respected leader in the cannabis industry for over a decade. Her “in the trenches” operational success and deep, global relationships led her to be coined “Wonder Woman” in the 2023 Women of Influence issue of Cannabis Now Magazine. Fluent in German, Jamie spent decades in the global real estate investment and finance world on three continents. She currently sits on the advisory boards of Dope Drinks, Marley One, Cellotex Dev Ltd, Global Cannabis Network Collective (GCNC), Lift & Co, and Alpen Group AG.
Jamie founded and leads The New Holland Group, a global consulting firm serving clients with international business development & strategy, seed to sale operations, branding & marketing, effective capital raising, executive coaching, cross border IP licensing, celebrity partnerships, buy & sell side M&A, and financial turnarounds. Client referrals have been New Holland Group’s only source of business and business is booming!
Before New Holland Group, Jamie spent seven years, including three as the President & CEO, of Bhang Inc. [CSE:BHNG] one of the world’s most-awarded and recognized cannabis edible brands, famous for its infused chocolate bars. She led the company’s diverse executive team, managed the “expansion through licensing” plan, ran the capital markets division, and was the face of the brand – catapulting Bhang from a California favorite to a multi-state and multi-national phenomenon. When Jamie exited Bhang the brand had been distributed in 7 US states and 10 countries through licensing deals with the likes of Trulieve, [CSE:TRUL], Indiva [TSX:NDVA] and Origin House [CSE:OH] (now Cresco). Jamie served four years as the Vice Chairman of Bhang’s Board and served on the Board’s audit committee.
Jamie is a popular speaker with competence in the areas of global expansion, ESG, IP & brand licensing, real estate acquisition, creative deal structuring, celebrity partnerships, business development, and leadership. Jamie can be reached at jamie@new-holland.group.

David Hyde, M.Sc., CPC has worked in the cannabis industry since 2013, when he consulted for a majority of Canada’s first medical cannabis companies. Over the past 11 years, David has started 7 companies in the cannabis sector, sold a leading cannabis business consultancy he founded, worked with multiple governments on cannabis policy, provided strategic guidance to some of the world’s largest cannabis companies, and brokered numerous cannabis M&A transactions globally.

As David continues to offer his expertise and unique experience to the evolving cannabis industry, you can find him leading his group of companies to the forefront of the cannabis sector.

Founder|CEO of Hyde Advisory & Investments Inc., a company focused on cannabis sector mergers, acquisitions, joint ventures, and partnerships. HAI has an 8-person team with 60+ Cannabis/CBD business listings in North America and globally: www.hydeadvisory.com

Founder|Managing Director of CannaNavigators, a Canada-based, global cannabis, hemp & psychedelics consultancy focused on licensing, compliance & security with experience in 30+ countries: www.cannanavigators.com.

Founder|Partner of Cannabis Global Consultants (CGC), a collective of 4 leading cannabis consultancies offering turnkey design, strategy & implementation support to cannabis businesses/start-ups and governments globally: www.cannabisglobalconsultants.com

David Hyde, M.Sc., CPC has worked in the cannabis industry since 2013, when he consulted for a majority of Canada’s first medical cannabis companies. Over the past 11 years, David has started 7 companies in the cannabis sector, sold a leading cannabis business consultancy he founded, worked with multiple governments on cannabis policy, provided strategic guidance to some of the world’s largest cannabis companies, and brokered numerous cannabis M&A transactions globally.

As David continues to offer his expertise and unique experience to the evolving cannabis industry, you can find him leading his group of companies to the forefront of the cannabis sector.

Founder|CEO of Hyde Advisory & Investments Inc., a company focused on cannabis sector mergers, acquisitions, joint ventures, and partnerships. HAI has an 8-person team with 60+ Cannabis/CBD business listings in North America and globally: www.hydeadvisory.com

Founder|Managing Director of CannaNavigators, a Canada-based, global cannabis, hemp & psychedelics consultancy focused on licensing, compliance & security with experience in 30+ countries: www.cannanavigators.com.

Founder|Partner of Cannabis Global Consultants (CGC), a collective of 4 leading cannabis consultancies offering turnkey design, strategy & implementation support to cannabis businesses/start-ups and governments globally: www.cannabisglobalconsultants.com

Beau Whitney is the founder and Chief Economist at Whitney Economics, a global leader in cannabis and hemp business consulting, data, and economic research. Whitney Economics is based in Portland, Oregon.

Serving an international clientele, Beau is considered one of the leading cannabis economists in the U.S. and globally. His applications of economic principles to create actionable operational and policy recommendations has been recognized by governments, and throughout the economic, investment, and business communities.

Beau has provided policy recommendations at the state, national and international levels and is considered an authority on cannabis economics and the supply chain.

David Hyde, M.Sc., CPC has worked in the cannabis industry since 2013, when he consulted for a majority of Canada’s first medical cannabis companies. Over the past 11 years, David has started 7 companies in the cannabis sector, sold a leading cannabis business consultancy he founded, worked with multiple governments on cannabis policy, provided strategic guidance to some of the world’s largest cannabis companies, and brokered numerous cannabis M&A transactions globally.

As David continues to offer his expertise and unique experience to the evolving cannabis industry, you can find him leading his group of companies to the forefront of the cannabis sector.

Founder|CEO of Hyde Advisory & Investments Inc., a company focused on cannabis sector mergers, acquisitions, joint ventures, and partnerships. HAI has an 8-person team with 60+ Cannabis/CBD business listings in North America and globally: www.hydeadvisory.com

Founder|Managing Director of CannaNavigators, a Canada-based, global cannabis, hemp & psychedelics consultancy focused on licensing, compliance & security with experience in 30+ countries: www.cannanavigators.com.

Founder|Partner of Cannabis Global Consultants (CGC), a collective of 4 leading cannabis consultancies offering turnkey design, strategy & implementation support to cannabis businesses/start-ups and governments globally: www.cannabisglobalconsultants.com

David Hyde, M.Sc., CPC has worked in the cannabis industry since 2013, when he consulted for a majority of Canada’s first medical cannabis companies. Over the past 11 years, David has started 7 companies in the cannabis sector, sold a leading cannabis business consultancy he founded, worked with multiple governments on cannabis policy, provided strategic guidance to some of the world’s largest cannabis companies, and brokered numerous cannabis M&A transactions globally.

As David continues to offer his expertise and unique experience to the evolving cannabis industry, you can find him leading his group of companies to the forefront of the cannabis sector.

Founder|CEO of Hyde Advisory & Investments Inc., a company focused on cannabis sector mergers, acquisitions, joint ventures, and partnerships. HAI has an 8-person team with 60+ Cannabis/CBD business listings in North America and globally: www.hydeadvisory.com

Founder|Managing Director of CannaNavigators, a Canada-based, global cannabis, hemp & psychedelics consultancy focused on licensing, compliance & security with experience in 30+ countries: www.cannanavigators.com.

Founder|Partner of Cannabis Global Consultants (CGC), a collective of 4 leading cannabis consultancies offering turnkey design, strategy & implementation support to cannabis businesses/start-ups and governments globally: www.cannabisglobalconsultants.com